Krystal Biotech, Inc.
- UEI
- H5VRRQJHRBL3
- CAGE
- 8BC06
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- krystalbio.com
- Founded
- 2016
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Ascendis Pharma, Inc. | — | 325412 Pharmaceutical Preparation Manufacturing |
| Sanofi Genzyme | Cambridge, MA | 325412 Pharmaceutical Preparation Manufacturing |
| TG Therapeutics Inc. | Morrisville, NC | 325412 Pharmaceutical Preparation Manufacturing |
| Enyx Therapeutics LLC | New York, NY | — |
| Amylyx Pharmaceuticals Inc. | — | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
About the company
Krystal Biotech, Inc. is a gene therapy biotechnology company focused on developing and delivering medicines to patients with genetic life threatening or rare diseases using an HSV 1 based gene delivery platform. Krystal's first commercial product, VYJUVEK®, is a gene therapy for dystrophic epidermolysis bullosa. The company provides pharmaceuticals, hematology products, and gene therapies like VYJUVEK to the federal government through contract vehicles such as Federal Supply Schedule contracts and Blanket Purchase Agreements.
Krystal Biotech currently holds a multiple-award Federal Supply Schedule contract through the Department of Veterans Affairs (VA) Veterans Health Administration Veterans Integrated Service Network 12 for Schedule 65 IB drugs, pharmaceuticals, and hematology-related products. The company was also awarded a single-award Blanket Purchase Agreement (BPA) valued at $1,296,582.70 by the VA National Acquisition Center to provide VYJUVEK gene therapy treatment through September 2024. Additionally, Krystal Biotech has an interim FSS Schedule 65 IB agreement with VA Network 12 for $25,000 in pharmaceuticals and hematology products through January 2024. The VA has demonstrated its intent to procure Krystal's VYJUVEK gene therapy through the BPA vehicle to improve access for veterans. The FSS contracts enable streamlined procurement of the company's pharmaceutical offerings across the VA healthcare system. These awards facilitate the VA's provision of Krystal Biotech's therapies and products to support treatment of genetic diseases and hematological conditions among veteran patients.
Quick answers
Is Krystal Biotech, Inc. registered in SAM.gov?
Krystal Biotech, Inc.'s SAM.gov registration expired on February 14, 2026.
On GovTribe
See Krystal Biotech, Inc.'s full federal record
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors